hotspot -WSS

hotspot

author：knowledge 2025-09-28 23:30:04 - browse：17

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Creating egg and sperm cells from stem cells raises ethical issues

hotspot

WSS

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Nurses recount patients attacks

Creating egg and sperm cells from stem cells raises ethical issues

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

hotspot

hotspot

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Nurses recount patients attacks

How one medical school became remarkably diverse

World's first CRISPR

Malaria cases in Florida and Texas: Here’s what you need to know

CRISPR pioneers react to Casgevy, first gene

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout LOUD podcast: A CRISPR milestone, biotech mixology

23andMe had bad news about my health. I wish a person had delivered it

CVS Caremark has created a new ploy: the drug ‘rebate credit’

hotspot

U.K. researchers warn about biases in medical devices, algorithms

Why medical students are struggling with mental health

Physicians and social media: If you see something, say something?

CRISPR pioneers react to Casgevy, first gene

Orchard's therapy for neuron disease in children wins FDA approval

Stop the failed accountable care organization experiment

knowledge

hotspot

focus

focus